PTM Antibody development service

Exonbio leverages SPIN® technology to develop PTM Antibody that are highly specific to post-translational modifications such as phosphorylation, methylation, glycosylation, ubiquitination, acetylation, and more.

Benefits

Powerful counter selection

Counter selection to significantly increase efficiency. >90% of clones isolated are post-translation modification specific.

High Specificity

Counter selection helps in developing antibodies highly specific to the modification

Large variety of modification

Phosphorylation, methylation, glycosylation ubiquitation, acetylation and more.

High affinity

Antibodies generated against PTM range around single digit nanomolar KD

Benefits

Powerful counter selection

· Counter selection to significantly increase the efficiency

· >90% of clones isolated are post translation modification specific

High Specificity

Counter selection helps in developing antibodies highly specific to the modification

Large variety of modification

Phosphorylation, methylation, glycosylation ubiquitation, acetylation and more.

High affinity

Antibodies generated against PTM range around single digit nanomolar KD

PTM antibody development with SPIN® tech

PTM antibody is critical in the study of signal transduction. Post-translational modification (PTM) is one of the mechanisms that enables the massive functional extension from the genome to the proteome, allowing each translated protein to act in specific ways, at specific times, and in specific cells and tissues. Counter selection using non-modified peptide makes it more effective to isolate antibodies against the modification site.

SPIN® technology allows to generate large number of PTM specific antibodies.

Service Highlights

Proven track record of 100% success rate

Identify antibody pairs by epitope binning

Affinity ranking using Biacore kinetic analysis

Royalty free antibodies

Contact us to get started with your next research initiative and make a big difference in a successful PTM antibody campaign.